{
    "topic": "healthcare",
    "source": "The Atlantic",
    "bias": 0,
    "url": "https://www.theatlantic.com/politics/archive/2018/05/big-pharma-gets-a-big-win-from-trump/560219/",
    "title": "Big Pharma Gets a Big Win From Trump",
    "date": "2018-05-12",
    "authors": "",
    "content": "One of the major pieces of the plan that Trump outlined Friday is an ongoing effort to change the federal government \u2019 s 340B Drug Pricing Program , which provides rebates to hospitals that treat a high share of Medicaid and uninsured patients . Those rebates are intended to lower the cost of care by forcing drug manufacturers to provide medications\u2014especially high-cost drugs for chronic conditions\u2014at cheaper prices to the neediest populations . But the $ 18 billion 340B program has been the setting for a war between drug manufacturers , who claim hospitals are simply pocketing the savings and not passing them on to patients , and the hospitals themselves . They claim drug manufacturers aren \u2019 t actually lowering prices , and instead are using the rebates as an excuse to increase their list prices .\nIn a policy document released Friday , the White House described its commitment to requiring that safety-net hospitals \u201c use their 340B drug discounts to provide care to more low-income and vulnerable patients. \u201d But an earlier move from the administration undercuts that commitment . Late last year , the Centers for Medicare and Medicaid Services slashed the 340B program to the tune of somewhere between $ 900 million to $ 1.65 billion , effectively siding with drug manufacturers who say the rebates aren \u2019 t worthwhile .\nTrump also seemed to take aim at a longtime industry foe in his speech : pharmacy benefits managers , or PBMs . PBMs function as industry middlemen , administering the prescription-drug programs for large insurance programs covering the majority of Americans . These companies handle negotiations between insurers and drug manufacturers on drug prices , including managing rebates from manufacturers that are designed to entice insurers into accepting certain medications on their plans . Drug manufacturers argue that PBMs have wrangled too-high rebates that they keep to themselves instead of passing on to consumers .\nIn its policy document , the White House vaguely committed to \u201c requiring Pharmacy Benefit Managers to act in the best interests of patients. \u201d Trump was much more forceful in his remarks . \u201c We \u2019 re very much eliminating the middlemen , \u201d Trump said , apparently referring to PBMs . \u201c The middlemen became very , very rich . \u201d\nDrug companies argue that limiting the 340B discounts and PBM rebates will reduce the consumer costs , especially for elderly people receiving their health care through Medicare Part D. But on that front , Trump has also walked back a major campaign pledge : allowing Part D to negotiate directly with insurers to lower costs of the drugs it offers . Trump said in his speech Friday that \u201c we will have tougher negotiation , \u201d and the policy blueprint released by the White House pushes for \u201c allowing greater flexibility in benefit design to encourage better price negotiation. \u201d But that policy doesn \u2019 t seem likely to affect the baseline negotiating capacity of the program : Congress would probably need to pass legislation to allow the health and human-services secretary to make deals with drug companies . Without that legislation in place , Trump has little executive authority to change anything .",
    "content_original": "One of the major pieces of the plan that Trump outlined Friday is an ongoing effort to change the federal government\u2019s 340B Drug Pricing Program, which provides rebates to hospitals that treat a high share of Medicaid and uninsured patients. Those rebates are intended to lower the cost of care by forcing drug manufacturers to provide medications\u2014especially high-cost drugs for chronic conditions\u2014at cheaper prices to the neediest populations. But the $18 billion 340B program has been the setting for a war between drug manufacturers, who claim hospitals are simply pocketing the savings and not passing them on to patients, and the hospitals themselves. They claim drug manufacturers aren\u2019t actually lowering prices, and instead are using the rebates as an excuse to increase their list prices.\n\nIn a policy document released Friday, the White House described its commitment to requiring that safety-net hospitals \u201cuse their 340B drug discounts to provide care to more low-income and vulnerable patients.\u201d But an earlier move from the administration undercuts that commitment. Late last year, the Centers for Medicare and Medicaid Services slashed the 340B program to the tune of somewhere between $900 million to $1.65 billion, effectively siding with drug manufacturers who say the rebates aren\u2019t worthwhile.\n\nTrump also seemed to take aim at a longtime industry foe in his speech: pharmacy benefits managers, or PBMs. PBMs function as industry middlemen, administering the prescription-drug programs for large insurance programs covering the majority of Americans. These companies handle negotiations between insurers and drug manufacturers on drug prices, including managing rebates from manufacturers that are designed to entice insurers into accepting certain medications on their plans. Drug manufacturers argue that PBMs have wrangled too-high rebates that they keep to themselves instead of passing on to consumers.\n\nIn its policy document, the White House vaguely committed to \u201crequiring Pharmacy Benefit Managers to act in the best interests of patients.\u201d Trump was much more forceful in his remarks. \u201cWe\u2019re very much eliminating the middlemen,\u201d Trump said, apparently referring to PBMs. \u201cThe middlemen became very, very rich.\u201d\n\nDrug companies argue that limiting the 340B discounts and PBM rebates will reduce the consumer costs, especially for elderly people receiving their health care through Medicare Part D. But on that front, Trump has also walked back a major campaign pledge: allowing Part D to negotiate directly with insurers to lower costs of the drugs it offers. Trump said in his speech Friday that \u201cwe will have tougher negotiation,\u201d and the policy blueprint released by the White House pushes for \u201callowing greater flexibility in benefit design to encourage better price negotiation.\u201d But that policy doesn\u2019t seem likely to affect the baseline negotiating capacity of the program: Congress would probably need to pass legislation to allow the health and human-services secretary to make deals with drug companies. Without that legislation in place, Trump has little executive authority to change anything.",
    "source_url": "www.theatlantic.com",
    "bias_text": "left",
    "ID": "7ThaFKxr7MNgPMwr"
}